FDA Approves Twice-Yearly Shot for HIV Prevention

(MedPage Today) — The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents, Gilead Sciences announced on Wednesday.
An injectable HIV-1 capsid inhibitor…